Today, $SYK (+4,34%) 20 shares have moved into my Pie portfolio! 📥💰
Stryker is currently still dealing with the fallout from an Iranian cyberattack in March 2026 that caused outages worldwide. 💻⚔️
Stryker has responded and plans to significantly harden its systems against cyberattacks, which will also put pressure on profits in the short term, as substantial investments are required. 💸🛡️
However, I still consider Stryker’s continued long-term success to be very realistic and view the cyberattack and its consequences as a favorable opportunity to buy in, since the company’s moat remains intact: 📈🏰
- High switching costs (Switching Costs): Customers would face enormous costs if they switched systems and would have to completely retrain their staff. Furthermore, switching involves high risks that no one wants to take, especially in the operating room. 🏥⚠️
- FDA approvals & patents: Approvals that have already been granted act as a protective shield. Competitors would have to invest hundreds of millions to even get to where Stryker already is. 🔬📜
- Strong Sales Network: Stryker can rely on a first-class, deeply established global sales network. 🌐🤝
Last but not least, Stryker has consistently outperformed the MSCI World Index 📊🚀—which is exactly why it’s one of the high-quality companies I’m very happy to weight more heavily in my portfolio. 💼✨
